Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRY^SM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

“The data from the SYMMETRY trial presented at the Perspectives in Melanoma XIII Conference shows an important connection between patients’ baseline level of LDH (lactate dehydrogenase), an established biomarker in melanoma, and treatment outcome with elesclomol,” said Dr. O’Day. “Patients with low and normal baseline levels of LDH showed an improvement in progression free survival (PFS), the primary endpoint of the study. The OS (overall survival) data for these groups are still highly censored and evolving; no difference has been observed to date between the treatment and control arms. In contrast, patients with high baseline level of LDH showed no PFS benefit and a decreased survival time relative to the control arm. These results, along with the results of other recent randomized clinical trials, suggest that baseline LDH status may evolve from a prognostic factor for the disease to a potentially predictive factor for treatment. This could pave the way for a more personalized approach to treating this disease that considers markers such as LDH in determining an optimal approach to therapy.”

“We believe there are three emerging findings from the SYMMETRY trial that are important for the future of the elesclomol program,” said Vojo Vukovic, M.D., Ph.D., Senior Vice President and Chief Medical Officer, Synta Pharmaceuticals. “First, there are clear signs of clinical benefit in the normal LDH population. In this patient group, which represents 68% of the trial population, the PFS endpoint was achieved. Second, any potential adverse effect on survival in favor of the control arm appears to be restricted to the high LDH patient population. Finally, and importantly in considering development of elesclomol beyond melanoma, there were no substantial differences in Grade 3 or 4 toxicities between the two arms of the trial, consistent with safety findings from prior trials, indicating that elesclomol was well tolerated.”

“Additional survival data, as well as a further understanding of the interaction between oxidative stress induction and LDH level, will be important for determining the future of the program,” continued Dr. Vukovic. “Both the elesclomol oxidative stress mechanism and LDH relate to metabolic pathways. Together with our academic collaborators we are actively investigating the connection between the two, and expect to present initial results at scientific meetings later this year. We expect to present SYMMETRY survival data with 12 months minimum follow-up, and announce further decisions related to the future of the elesclomol program, in the first half of 2010.”